Nutraveris

Archives

Thursday, June 28, 2012
Category : NEWS, NUTRILEGAL, food safety | Author : experts | Comment : No Comments
Tags: , , , , , , , , , , ,

ANSES issued an internal request on 30 June 2011 for an assessment of the nutritional health benefits and risks of high-intensity sweeteners after the publication of 2 studies highlighting safety issues (see the news in brief of January 17th 2011, March 8th 2011, and March 24th 2011). The assessment is currently under way but a preliminary progress report was published dealing specifically with the effects of consumption of these sweeteners by pregnant women. As regards a potential risk during pregnancy, ANSES considers that the scientific data available on pregnant women are not sufficient to provide a conclusion. Moreover, ANSES emphasizes that no studies show any nutritional benefits of consuming these substances during pregnancy.

These conclusions will be revised as necessary with regard to ANSES’s work on the general population, for which the analyses may be extrapolated to pregnant women. ANSES will issue, if necessary, recommendations based on all the available data.

It should be noted that EFSA’s conclusions regarding a possible reassessment of the acceptable daily intake (ADI) for aspartame are expected in late 2012.

Reference: www.anses.fr

Tuesday, June 26, 2012
Category : NEWS, CLAIMS, CONVICTIONS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags: , ,

This review presents the influence of phytosterols on the development of atherosclerosis. The plasma cholesterol-reducing effect of phytosterols has been recognized in several studies, but the usefulness of phytosterols in preventing coronary heart disease remains controversial. Phytosterols may also induce inflammation and reduce cholesterol efflux from macrophages, conditions that are directly implicated in the development of atherosclerosis.

Reported to the major problem in health and nutrition claims, one might question the benefit of lowering cholesterol by phytosterols which would lead to atherosclerosis, and then why these ingredients gained authorized claims while others, such as plants, are systematically denigrated by EFSA!

Reference: Lottenberg AM, Bombo RP, Ilha A, Nunes VS, Nakandakare ER, Quintão EC. Do clinical and experimental investigations support an antiatherogenic role for dietary phytosterols/stanols? IUBMB Life. 2012 Apr;64(4):296-306.

Thursday, June 14, 2012
Category : NEWS, CLAIMS | Author : experts | Comment : No Comments
Tags: , , , ,

Training AFIPA – Tuesday 19th of june 2012 – Hôtel Bedford, 17 rue de l’Arcade, Paris 8e.

This program will be dedicated to the development and market access of food supplement relating to the new European Regulation.
Key points for successful development will be presented: players, regulatory texts, labelling requirements, authorized claims… You’ll be able to connect directly with experts at lunch time.
Ask for the program: contact@nutraveris.com
Tuesday, June 12, 2012
Category : NEWS, CLAIMS | Author : experts | Comment : No Comments
Tags: , , , ,

EFSA has just published 12 new opinions containing 18 generic health claims reassessed. The majority of health claims in this batch concerns probiotics. Those were previously negatively evaluated by the scientific European authority because of insufficient characterization. Henceforth, when the characterization is considered sufficient by EFSA, this is the scientific substantiation which is lacking… Indeed, no reassessed probiotic has received a positive opinion for an action about immunity. Other ingredient/application couples were also reevaluated e.g. lutein/vision, vitamin K2/cardiovascular health, however only 2 positive opinions have been given by EFSA: prunes/bowel function and α-cyclodextrin/glycaemic responses. Therefore, nothing very surprising… and the number of claims on the pending list is reduced.
Thursday, June 7, 2012
Category : NEWS, food safety | Author : experts | Comment : No Comments
Tags: , ,

Following the report of two new cases of death due to heart attack associated with energy drink consumption, the ANSES asks to health care professionals to indicate all adverse events potentially linked to these energy drinks. The term “energy drink”, which has no regulatory frame, corresponds to drinks containing stimulating ingredients as taurine, caffeine, guarana or ginseng. In addition to the harmful effects of the combination of these drinks with alcohol, the ANSES states that 13 energy drink-associated pathologies, for which the cause and effect relationship is probable or possible, have been reported since 2008. These pathologies are mainly neurologic, psychiatric and cardiovascular diseases.
The ANSES reminds that these drinks are only for adults, and should be consumed in moderation. Energy drinks are not recommended for pregnant women, and conversely to energetic drinks, these they are not adapted for an intense physical activity.

Source: www.anses.fr